MedPath

FDA Approves Verrica's Ycanth, First Treatment for Molluscum Contagiosum

The FDA has granted approval to Verrica Pharmaceuticals for Ycanth, marking it as the first treatment specifically for molluscum contagiosum, a common viral skin infection.

The U.S. Food and Drug Administration (FDA) has officially approved Verrica Pharmaceuticals' Ycanth, making it the first treatment available for molluscum contagiosum. This approval represents a significant milestone in the treatment of this common viral skin infection, which primarily affects children but can also occur in adults. Ycanth's approval is based on its demonstrated efficacy and safety in clinical trials, offering a new therapeutic option for patients suffering from this condition. The development of Ycanth underscores the importance of continued innovation in the pharmaceutical industry to address unmet medical needs.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves New Vial Sizes of Niktimvo for Chronic Graft-Versus-Host Disease

The FDA has approved Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for chronic graft-versus-host disease (GVHD) after two prior systemic therapies.
Niktimvo is the first FDA-approved treatment targeting CSF-1R to reduce inflammation and fibrosis in chronic GVHD, offering a novel approach for patients.

FDA Approves Syndax's Revuforj, a First-in-Class Menin Inhibitor for Acute Leukemia

The FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for adults and children with relapsed or refractory acute leukemia with KMT2A rearrangement.
Revuforj, a menin inhibitor, showed a complete remission or complete remission with partial hematologic recovery in 21.2% of study participants, with a median response duration of 6.4 months.

FDA Approves Syndax's Revuforj (Revumenib) for Relapsed/Refractory KMT2A-Rearranged Acute Leukemia

The FDA has approved Revuforj (revumenib) as the first menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation in patients aged one year and older.
In the AUGMENT-101 trial, 21% of patients achieved complete remission with partial hematological recovery, with a median response duration of 6.4 months.

FDA Approves Syndax's Revuforj (Revumenib) for Relapsed or Refractory Acute Leukemia with KMT2A Translocation

The FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) as the first and only menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation in patients aged one year and older.
Revuforj's approval was based on the Phase I/II AUGMENT-101 trial, where 21% of patients achieved complete remission with partial hematological recovery, and 23% underwent stem cell transplantation.

FDA Approves Revuforj (revumenib) for Relapsed/Refractory Acute Leukemia with KMT2A Translocation

The FDA has approved Revuforj (revumenib) as the first menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation in adults and children.
Approval was based on the AUGMENT-101 trial, which showed a 21% complete remission rate in patients treated with Revuforj.

FDA Approves Revuforj (revumenib) for Relapsed/Refractory Acute Leukemia with KMT2A Translocation

The FDA has approved Revuforj (revumenib) as the first and only menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation in adults and pediatric patients.
Approval was based on the AUGMENT-101 trial, which showed robust and durable remission rates in R/R acute leukemia patients with a KMT2A translocation.

PYC Therapeutics' VP-001 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Type 11

PYC Therapeutics has been granted Orphan Drug Designation by the FDA for VP-001, a drug candidate targeting Retinitis Pigmentosa type 11 (RP11).
VP-001 is currently in clinical trials, representing a significant advancement for treating this rare childhood blinding disease with no approved therapies.

FDA Approves VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

The U.S. Food and Drug Administration (FDA) has approved VYVGART Hytrulo, developed by argenx, for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP), marking a significant advancement in the management of this rare autoimmune disease.

FDA Approves Krystal Biotech's Vyjuvek, a Topical Gene Therapy for Dystrophic Epidermolysis Bullosa

The FDA has approved Vyjuvek, Krystal Biotech's topical gene therapy, marking the first treatment of its kind for dystrophic epidermolysis bullosa.
Vyjuvek is approved for patients aged six months and older with either recessive or dominant forms of dystrophic epidermolysis bullosa.

Reference News

[1]
Recon: FDA approves Verrica's Ycanth, first treatment for ...
raps.org · Jan 1, 2022

ReconJoanne S. Eglovitch covers topics on biologics, biosimilars, vaccines, diagnostics/IVDs, medical devices, pharmaceu...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy